Biotech Values

[DewDiligence]

Russian firm, Biocad, to manufacture FoB’s in Brazil:

http://www.themoscowtimes.com/business/article/wooed-by-state-spending-russian-drugmaker-biocad-bets-on-brazil/488061.html

The Biocad facility will produce the cancer-fighting trastuzumab [Herceptin], as well as pegylated interferon against rheumatoid arthritis, and rituximab [Rituxan] to combat hepatitis type C.

Rituxan for HCV would be a neat trick, LOL. (They meant to say Ritxuan for RA and peg-IFN for HCV.)

In some emerging markets, a cheap generic version of peg-IFN might hang around awhile even after all-DAA regimens are approved in major markets.